Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.
Colorectal Cancer
Data from this 28-country multi-institutional effort helped the Food and Drug Administration (FDA) approve this combination more quickly in December 2024, giving patients with BRAF V600E-mutant mCRC a new and effective first-line treatment choice.
